UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 5, 2017
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 001-33038 | | 84-1475642 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
One First Avenue, Parris Building 34, Navy Yard Plaza Boston, Massachusetts | | 02129 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(617) 259-1970
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 5, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a press release announcing updated results from the 20-mg expansion cohort in the Company’s ongoing Phase 1, multicenter, dose-escalation study of its gene therapy candidate Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma. Such results will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6, 2017 in Chicago, Illinois. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits |
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release dated June 5, 2017. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | ZIOPHARM Oncology, Inc. |
| | | |
| Date: June 5, 2017 | | | | By: | | /s/ Kevin G. Lafond |
| | | | | | Name: Kevin G. Lafond |
| | | | | | Title: Senior Vice President, Chief Accounting Officer and Treasurer |
3
INDEX OF EXHIBITS
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release dated June 5, 2017. |
4
